Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study

Journal of the American College of Cardiology

Volumn 28, Issue 3, 1996, Pages 700-706

  Bianconi, Leopoldo ^a,b   Mennuni, Mauro ^a   Lukic, Vjerica ^a   Castro, Antonio ^a   Chieffi, Mara ^a   Santini, Massimo ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROPAFENONE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0030245557     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00230-6     Document Type: Article

References (27)

1. 1. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman N, Friedman PL. Long term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988;12: 1005-11.
2. 2. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm: a meta-analysis of randomized clinical trials. Circulation 1990;82:1106-16.
3. 3. Fain ES, Dorian P, Davy JM, Kates R, Winkle R. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation 1986;73: 1334-41.
4. 4. Singer I, Guarnieri T, Kupersmith J. Implanted automatic defibrillators: effects of drugs and pacemakers: PACE 1988;11:2250-62.
5. 5. Echt DS, Blank JN, Barbey JT, Coxe DR, Cato E. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: sodium channel block and action potential prolongation. Circulation 1989;79:1106-17.
6. 6. Hernandez R, Mann DE, Breckinridge S, Reiter MJ. Effects of flecainide on defibrillation threshold in the anesthetized dog. J Am Coll Cardiol 1989;14: 777-81.
7. 7. Peters W, Gang ES, Okazaky H, et al. Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog. Am Heart J 1991;122:1355-60.
8. 8. Jung W, Manz M, Pizzulli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70:1023-7.
9. 9. Szekely P, Wynne NA, Pearson DT, Batson GA, Sideris DA. Direct current shock and antidysrhythmic drugs. Br Heart J 1970;32:209-18.
10. 10. Sagristà-Sauleda J, Permanyer-Miralda G, Soler-Soler J. Electrical cardioversion after amiodarone administration. Am Heart J 1992;123:1536-42.
11. 11. Hall JI, Wood DR. Factors affecting cardioversion of atrial arrhythmias with special reference to quinidine. Br Heart J 1968;30:84-90.
12. 12. Rossi M, Lown B. The use of quinidine in cardioversion. Am J Cardiol 1967;19:234-8.
13. 13. Sodermark T, Edhag Y, Sjogren A, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. Br Heart J 1975;37:486-92.
14. 14. Van Gelder IC, Crijns HJ, Van Gilst WH, De Langen CD, Van Wijk LM, Lie KI. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989;63:112-6.
15. 15. Sagristà-Sauleda J, Permanyer-Miralda G, Soler-Soler J. Cardioversion electrica bajo la action de la quinidina. Rev Esp Cardiol 1990;43:604-9.
16. 16. Guarnieri T, Tomaselli G, Griffith LSC, Brinker J. The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation. PACE 1991;14:1007-12.
17. 17. Kerr CR, Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol 1988;61:914-6.
18. 18. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:819-9.
19. 19. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy of refractory atrial fibrillation and atrial flutter: a staged care approach with new antiarrhtyhmic drugs. J Am Coll Cardiol 1990;15:698-707.
20. 20. Grey E, Silverman DI. Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. PACE 1993;16:2235-40.
21. 21. Morris JA, Gardner RJ. Calculating confidence intervals for relative risk (odds ratio) and standardised ratios and rate. Br Med J 1988;296:1313-16.
22. 22. Bianconi L, Boccadamo R, Pappalardo A, Broglia R, Pistolese M. Fibrillazione e flutter atriale. Controllo immediato e conversione a ritmo sinusale con propafenone endovena. G Ital Cardiol 1987;17:653-60.
23. 23. Feld GK, Chen PS, Nicod P, Fleck P, Meier D. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990;66:378-83.
24. 24. Murdoch CJ, Kyles AE, Yeung-Lai-Wah JA, Qi A, Vorderbrugge S, Kerr CR. Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990;66:755-7.
25. 25. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967;29: 469-87.
26. 26. Kumagai K, Akimitsu S, Kawahira K, et al. Electrophysiological properties in chronic lone atrial fibrillation. Circulation 1991;84:1662-8.
27. 27. Shlepper M. Propafenone, a review of its profile. Eur Heart J 1987;8 Suppl A:27-32.